Atria Investments Inc Acquires New Holdings in Artivion, Inc. $AORT

Atria Investments Inc bought a new position in shares of Artivion, Inc. (NYSE:AORT) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 7,841 shares of the company’s stock, valued at approximately $244,000.

Other hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. raised its position in Artivion by 2.4% in the 1st quarter. Principal Financial Group Inc. now owns 206,777 shares of the company’s stock worth $5,083,000 after purchasing an additional 4,749 shares during the last quarter. Invesco Ltd. increased its stake in Artivion by 27.9% in the first quarter. Invesco Ltd. now owns 341,656 shares of the company’s stock valued at $8,398,000 after purchasing an additional 74,589 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Artivion during the 2nd quarter worth $669,000. Fred Alger Management LLC acquired a new position in shares of Artivion in the 1st quarter valued at approximately $2,969,000. Finally, Diker Management LLC acquired a new stake in shares of Artivion during the first quarter worth $369,000. 86.37% of the stock is owned by institutional investors.

Insider Activity

In other Artivion news, SVP Jean F. Holloway sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $46.18, for a total value of $461,800.00. Following the transaction, the senior vice president directly owned 169,169 shares in the company, valued at $7,812,224.42. The trade was a 5.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Amy Horton sold 1,789 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $44.62, for a total value of $79,825.18. Following the transaction, the chief accounting officer directly owned 144,862 shares in the company, valued at $6,463,742.44. This represents a 1.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 78,968 shares of company stock worth $3,496,982. 7.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on AORT shares. Citigroup reissued an “outperform” rating on shares of Artivion in a research report on Friday, October 10th. Citizens Jmp lifted their target price on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Stifel Nicolaus boosted their target price on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Wall Street Zen upgraded Artivion from a “hold” rating to a “buy” rating in a research note on Monday, August 25th. Finally, JMP Securities increased their price target on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.11.

Artivion Stock Performance

NYSE:AORT opened at $47.69 on Thursday. The company has a fifty day moving average of $42.61 and a 200-day moving average of $35.96. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.04. The firm has a market capitalization of $2.25 billion, a P/E ratio of -113.54 and a beta of 1.65. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. The firm’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.